Abstract #3652

Safety and diagnostic efficacy of Dotarem® (gadoteric acid) for MR mammography: Diagnosis vs. cytological findings

Matthias Hackenbroch¹, De Hua Chang¹, and David Maintz¹

¹Radiology, University Clinic of Cologne, Cologne, Germany

A non-interventional post-marketing surveillance study carried out between January 2012 and October 2013 on 1,537 patients in 15 centres showed that Dotarem® (Guerbet, Roissy, France) is an effective contrast agent for the identification of invasive ductal carcinomas. An MR mammography with the diagnosis of invasive ductal carcinoma was confirmed in 93.5% of all cases by means of a subsequent cytological examination. Overall, a diagnosis was able to be made in 99.2% of the cases. Adverse reactions occurred in 5 patients (0.3%). In 4 out of 5 of the patients the adverse events were not serious and in one patient the adverse events were serious.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.